Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Kaseb AO, et al. Among authors: nicholas c. Lancet Gastroenterol Hepatol. 2022 Mar;7(3):208-218. doi: 10.1016/S2468-1253(21)00427-1. Epub 2022 Jan 20. Lancet Gastroenterol Hepatol. 2022. PMID: 35065057 Free PMC article. Clinical Trial.
MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma.
Adelmann CH, Truong KA, Liang RJ, Bansal V, Gandee L, Saporito RC, Lee W, Du L, Nicholas C, Napoli M, Mino B, South AP, Proby CM, Leigh IM, Coarfa C, Flores ER, Tsai KY. Adelmann CH, et al. Among authors: nicholas c. J Invest Dermatol. 2016 Sep;136(9):1920-1924. doi: 10.1016/j.jid.2016.05.110. Epub 2016 Jun 9. J Invest Dermatol. 2016. PMID: 27293029 Free PMC article. No abstract available.
Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates.
Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Chilukuri S, Charpiot E, Adelmann CH, Ching G, Nguyen TN, Nicholas C, Thomas VD, Migden M, MacFarlane D, Thompson E, Shen J, Takata Y, McNiece K, Polansky MA, Abbas HA, Rajapakshe K, Gower A, Spira A, Covington KR, Xiao W, Gunaratne P, Pickering C, Frederick M, Myers JN, Shen L, Yao H, Su X, Rapini RP, Wheeler DA, Hawk ET, Flores ER, Tsai KY. Chitsazzadeh V, et al. Among authors: nicholas c. Nat Commun. 2016 Aug 30;7:12601. doi: 10.1038/ncomms12601. Nat Commun. 2016. PMID: 27574101 Free PMC article.
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.
Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J, Ager C, Nicholas C, Jaiswal AR, Sun Y, Shah K, Balasubramanyam S, Li N, Wang G, Ning J, Zal A, Zal T, Curran MA. Jayaprakash P, et al. Among authors: nicholas c. J Clin Invest. 2018 Nov 1;128(11):5137-5149. doi: 10.1172/JCI96268. Epub 2018 Oct 15. J Clin Invest. 2018. PMID: 30188869 Free PMC article.
Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.
Murone M, Vaslin Chessex A, Attinger A, Ramachandra R, Shetty SJ, Daginakatte G, Sengupta S, Marappan S, Dhodheri S, Rigotti S, Bachhav Y, Brienza S, Traxler P, Lang M, Aguet M, Zoete V, Michielin O, Nicholas C, Johnson FM, Ramachandra M, McAllister A. Murone M, et al. Among authors: nicholas c. Mol Cancer Ther. 2016 Oct;15(10):2334-2343. doi: 10.1158/1535-7163.MCT-15-0974. Epub 2016 Jul 20. Mol Cancer Ther. 2016. PMID: 27439479
319 results